Open AccessA phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan ( XELOXIRI ) in patients with locally advanced rectal cancer
Author(s) -
Matsuda Chu,
Kudo Toshihiro,
Morimoto Yoshihiro,
Kagawa Yoshinori,
Tei Mitsuyoshi,
Ide Yoshihito,
Miyoshi Norikatsu,
Takahashi Hidekazu,
Uemura Mamoru,
Takemasa Ichiro,
Satoh Taroh,
Mizushima Tsunekazu,
Murata Kohei,
Doki Yuichiro,
Eguchi Hidetoshi
Publication year - 2023
Publication title -
annals of gastroenterological surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.308
H-Index - 15
ISSN - 2475-0328
DOI - 10.1002/ags3.12600
Subject(s) - oxaliplatin , medicine , capecitabine , irinotecan , colorectal cancer , neoadjuvant therapy , perioperative , oncology , total mesorectal excision , chemotherapy , clinical endpoint , surgery , gastroenterology , cancer , clinical trial , breast cancer
Purpose Addition of perioperative multi‐agent chemotherapy to the treatment strategy for locally advanced rectal cancer (LARC) may be a promising option. We conducted a phase II study to evaluate the safety and efficacy of capecitabine combined with oxaliplatin and irinotecan (XELOXIRI) as triplet neoadjuvant chemotherapy in patients with LARC. Methods Patients received neoadjuvant irinotecan and oxaliplatin and capecitabine and then underwent total mesorectal excision. The primary study endpoint was the pathological complete response (pCR) rate. Results Between June 2013 and December 2016, 55 patients were enrolled in the study. Forty‐two (77.8%) of 54 completed the study protocol. The pCR rate was 7.7% (95% CI 3.0% to 18.2%). The 3‐year local recurrence rate was 3.9%, the 3‐year disease‐free survival (DFS) rate was 77.3, and the 3‐year overall survival rate was 96.0%. Conclusion XELOXIRI neoadjuvant chemotherapy appears to be feasible and efficacious for patients with LARC. Although neoadjuvant XELOXIRI alone did not yield our expected pCR rate, the local recurrence rate, 3‐year DFS, and measures of safety met current standards.